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Abstract
Background—The prevalence of diabetes and hypertension has increased in HIV-positive 
populations but there is limited understanding of the role that ART programs play in the delivery 
of services for these conditions. The aim of this study is to assess the relationship between ART 
use and utilization of healthcare services for diabetes and hypertension.
Methods—Health and Aging in Africa: a Longitudinal Study of an INDEPTH Community in 
South Africa is a cohort of 5,059 adults. The baseline study collects biomarker-based data on HIV, 
ART, diabetes and hypertension and self-reported data on healthcare utilization. We calculated 
differences in care utilization for diabetes and hypertension by HIV and ART status and used 
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multivariable logistic regressions to estimate the relationship between ART use and utilization of 
services for these conditions, controlling for age, sex, body mass index (BMI), education and 
household wealth quintile.
Results—Mean age, BMI, hypertension and diabetes prevalence were lower in the HIV-positive 
population (all p<0.001). Multivariable logistic regression showed that ART use was significantly 
associated with greater odds of blood pressure (aOR 1.27 95% CI 1.04–1.55) and blood sugar 
measurement (aOR 1.26, 95% CI 1.05–1.51), counseling regarding exercise (aOR 1.57, 95% CI 
1.11–2.22), awareness of hypertension diagnosis (aOR 1.52, 95% CI 1.12–2.05) and treatment for 
hypertension (aOR 1.63, 95% CI 1.21–2.19).
Conclusions—HIV-positive patients who use ART are more likely to have received healthcare 
services for diabetes and hypertension. This apparent ART advantage suggests that ART programs 
may be a vehicle for strengthening health systems for chronic care.
INTRODUCTION
The establishment and scale-up of HIV antiretroviral treatment (ART) programs in sub-
Saharan Africa has been among the most successful global public health efforts in recent 
years. In recent years ART coverage in eastern and southern Africa has nearly doubled, from 
24% in 2010 to 54% in 2015, with over 10 million people living with HIV (PLWHIV) 
currently on ART in this region.1 The resulting health benefits have been very significant, 
including gains in adult life expectancy of more than a decade.2,3 As PLWHIV age on ART, 
the prevalence of comorbid non-communicable diseases,4 such as diabetes and hypertension, 
have also increased, with recent studies showing a diabetes prevalence of 13.7% in older 
African adults and hypertension in more than 50% of older adults in southern Africa.5–7 
However, evidence to guide programs and policies for those affected remains limited.8–12 As 
such, there is a pressing need for greater research at the intersection of these epidemics, 
especially in low and middle-income countries that face a dual burden of high HIV 
prevalence and rising cardiometabolic conditions coupled with weak health system 
infrastructure.13
The role of ART programs and their impact on health system performance in sub-Saharan 
Africa has been an area of controversy for many years. Some experts have expressed 
concern that ART programs may exacerbate health inequalities by directing scarce resources 
to PLWHIV or diverting those resources away from primary health care systems that serve 
the general adult population to HIV-related programs.14–16 In contrast, others have argued 
that ART programs may actually serve as a backbone on which to build stronger health 
systems by increasing the overall infusion of resources to the system and strengthening both 
human resources for health and systems for laboratory and clinical medicine that are 
common to ART programs and other types of healthcare service provision.14,17 Moreover, 
the marginal costs of adding these basic diagnostic and treatment services for diabetes and 
hypertension to existing ART programs is likely to be low, since clinical infrastructure and 
personnel are already in place. With little data to support or refute these claims, there 
remains a lack of clarity about the effect of ART programs on health system performance for 
conditions other than HIV.5,18–20
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Within a large cohort of adults aged >40 years in Agincourt, South Africa, this study aims to 
describe (1) differences in utilization of healthcare services for diabetes and hypertension 
among HIV-positive versus HIV-negative persons and (2) the relationship between ART use 
and healthcare service utilization for diabetes and hypertension among HIV-positive 
persons . We hypothesize that the HIV-infected individuals who utilize ART have greater 
access to diagnosis and care for comorbid diabetes and hypertension as compared to 
individuals not receiving ART, irrespective of their HIV-infection status. In essence we 
postulate that ART programs may provide a platform to strengthen health system 
performance for other chronic conditions.
METHODS
Overview of the HAALSI cohort
The Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in 
South Africa (HAALSI) aims to understand population aging in a rapidly transitioning 
community of rural northeast South Africa. The cohort consists of adults aged 40 and over 
and is nested within a health and demographic surveillance system (HDSS) covering the 
Agincourt sub-district adjacent to southern Mozambique.21 The sub-district is a rural region 
comprising 31 villages with high rates of migration. The local population is served by six 
clinics and two health centers along with three district hospitals that are located within 60 
km of the study site.
Enrollment in the HAALSI cohort, with participants randomly sampled from the Agincourt 
HDSS, began in November 2014 and closed in November 2015.22 Individuals 40 years and 
older as of July 1, 2014 who had been living in the study site for the 12 months prior were 
eligible for selection. A total of 6,281 women and men were selected for the main household 
survey in order to achieve a target sample size of 5,000 people. Those who participated in 
earlier studies and met the eligibility criteria were selected with 100 percent probability 
while the remainder of the sample was selected randomly from the 2013 HDSS census, 
stratifying on sex in order to achieve equal numbers of men and women.23
The baseline survey, upon which this analysis is based, included self-reported demographic, 
health and economic information, questions on self-reported healthcare service utilization 
for HIV, diabetes and hypertension, as well as anthropometry and laboratory studies. The 
survey was administered by trained, local fieldworkers who recorded participant responses 
in a Computer Assisted Personal Interview system. As part of the survey administration, 
these trained fieldworkers also collected blood through finger prick and prepared dried 
bloodspots (DBS) from each participant who consented to blood collection. The 
anthropometry and laboratory data included height, weight, blood pressure, and point-of-
care glucose. In addition, the DBS were later tested for HIV antibody and viral load in all 
consenting participants. The HIV screening and confirmatory enzyme-linked 
immunosorbent assays used were the Vironostika HIV 1/2 Ag/Ab MicroELISA System 
(Biomeriuex, France) and the Roche Cobas E411 Combi Ag (USA), respectively. The Viral 
Load Platform was Biomeriux NucliSens with a lower limit of detection of <100 copies by 
DBS.
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For those participants with a positive HIV antibody test, further testing for exposure to either 
emtricitabine (FTC) or lamivudine (3TC) was performed via dried blood spot (DBS). Study 
samples were analysed at the Pharmacokinetic Laboratory at the University of Cape Town in 
South Africa. A semi-quantitative LC/MS/MS assay with a lower limit of detection of 0.02 
μg/ml was validated for the determination of 3TC and FTC from DBS. The method 
consisted of a protein precipitation, followed by high performance liquid chromatography 
with MS/MS detection using gradient elution. An AB Sciex API 4000 mass spectrometer at 
unit resolution in the multiple reaction monitoring (MRM) mode was used to monitor the 
transition of the protonated precursor ions at m/z 248.0 and 230.2 to the product ions at m/z 
129.9 and 112.0 for emtricitabine and lamivudine, respectively. Electro Spray Ionisation 
(ESI) was used for ion production.24,25 Samples that fell above the lower limit of detection 
for either of the antiretroviral drugs tested were classified as positive for ART use. The time 
from ingestion to reaching this threshold has been estimated at 1.5 days for 3TC.24 Ethical 
approval for HAALSI was obtained from the University of the Witwatersrand, the Harvard 
T.H. Chan School of Public Health, and the Mpumalanga Provincial Research and Ethics 
Committee.
Defining HIV-infection, ART, and viral suppression
In this study, HIV infection status was defined using the result of the DBS antibody testing, 
rather than self-reported status. Those participants who tested positive for exposure to either 
FTC or 3TC were classified as ART users, irrespective of their self-reported HIV or ART 
status. Thus, ART exposure in this study is defined as a binary variable indicating that either 
a drug or drugs (FTC or 3TC or both drugs) were present in the DBS sample or no drug was 
present in the sample. All first and second line antiretroviral regimens in South Africa utilize 
one of these two drugs as part of a three drug combination. Finally, HIV viral load was 
measured using DBS viral load testing, allowing for a biological assessment of viral 
suppression. We define viral suppression based on the DBS results at <100 copies per ml, 
the lower limit of detection for the assay. We also provide a comparative assessment of the 
rate of viral suppression when it is defined as <400 copies per ml, the upper limit for routine 
viral load monitoring per South African guidelines and as <1000 copies per ml, the threshold 
for defining treatment failure per South African guidelines. We performed all supplementary 
analyses at each of these viral load thresholds.
Utilization of healthcare services for hypertension and diabetes—Measured 
height and weight were used to define body mass index (BMI) as well as diagnoses of 
hypertension and diabetes. Three blood pressure measurements were taken two minutes 
apart for each respondent, using a standard manual blood pressure cuff. The first 
measurement was dropped; the second and third measurements were averaged.26 
Hypertension was defined as a mean systolic blood pressure ≥140 mm Hg or diastolic blood 
pressure ≥90 mm Hg or self-reported use of medication for hypertension prescribed by a 
doctor, nurse or healthcare worker. Diabetes was defined as a fasting plasma glucose ≥7.0 
mmol/L or random plasma glucose ≥11.1 mmol/L measured at the time of interview or self-
reported use of medication for diabetes mellitus prescribed by a doctor, nurse or healthcare 
worker.27,28 Utilization of care for hypertension and diabetes was assessed using the 
following variables as reported by each participant: access to diagnosis (ever measurement 
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of blood pressure and ever measurement of blood sugar by a healthcare provider), receiving 
advice on lifestyle modification (advised by healthcare provider to change diet or exercise), 
awareness of diagnosis (told about diagnosis of hypertension or told about diagnosis of 
diabetes by healthcare provider) and access to treatment (self-reported use of medication for 
blood pressure or self-reported use of medication for blood sugar). The latter two outcomes 
were only assessed among those who met criteria for a diagnosis of the respective condition.
Analysis—We calculated descriptive demographic and health characteristics stratified into 
three groups: HIV-negative participants (HIV-negative), HIV-positive participants who were 
not currently using ART (HIV+/No ART) and HIV-positive participants who were current 
ART users based on FTC/3TC exposure testing (HIV+/ART users). Individual participants 
could only be assigned to one of these groups. Means were compared using one-way 
ANOVA and proportions using chi-squared tests. We then calculated the proportion of 
participants in the HIV+/ART user group who self-reported utilization of each of the NCD 
care metrics outlined above and compared this to the proportion of people in the HIV-
negative and HIV+/No ART groups who self-reported utilization of these same services.
Next, to test our central hypothesis, we used multivariable logistic regressions to assess the 
association between ART use and each of the following outcomes in terms of diagnosis and 
advice on lifestyle modification from a healthcare provider across the cohort: (1) ever receipt 
of a blood pressure measurement (2) ever receipt of a blood sugar measurement (3) ever 
receipt of advice to change diet and (4) ever receipt of advice to exercise. We then use 
logistic regression to assess the association between ART use and each of the following 
outcomes related to awareness of diagnosis and treatment of diabetes or hypertension among 
those who met criteria for a diagnosis of either condition: (5) awareness of diabetes 
diagnosis among diabetics, (6) awareness of hypertension diagnosis among hypertensives, 
(7) treatment receipt for diabetes among diabetics, (8) treatment receipt for hypertension 
among hypertensives. All models were adjusted for age, sex, BMI, household wealth index 
and educational attainment. The household wealth index is the quintile ranking of scores 
derived from principal components analysis of ownership of household items, livestock and 
vehicles.
As a sensitivity analysis, we also performed this multivariate regression to examine whether 
the relationship was preserved in self-reported ART and for the ART users who were also 
virally suppressed. As described previously, we examined these relationships using three 
different definitions of viral suppression (<100 copies, <400 copies and <1000 copies).
FINDINGS
HIV infection, ART and viral suppression in Agincourt, South Africa
Figure 1 depicts the HIV-positive population in the HAALSI study stratified by ART use and 
viral suppression. Among 4,560 participants who underwent DBS testing for HIV antibody, 
1,048 (23%) were found to be HIV-positive. As discussed in detail elsewhere, this is a high 
HIV prevalence given the older age of this cohort.22 Moreover, 662 (64%) of these HIV-
positive participants were also positive for exposure to FTC or 3TC, though only 450 or 68% 
of the ART users as defined by DBS exposure testing also self-reported ART use. Finally, 
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among the ART users, 479 (72%) were virally suppressed where viral suppression was 
defined by a viral load of <100 copies, the lower limit of assay detection in this study. When 
using the alternative viral load threshold of <400 copies, 549 (83%) were suppressed while 
594 (90%) were suppressed at a threshold of <1000 copies.
Diabetes and hypertension in the HIV-positive population
The demographic and health data, displayed in Table 1, show that age, BMI and mean 
systolic blood pressure are all lower among the HIV-positive population, both in those on 
and off ART, as compared to the HIV-negative population (p<0.001). There is a lower 
proportion of HIV-positive participants who have comorbid hypertension (HIV-negative: 
63.7%, HIV+/No ART: 43.5%, HIV+/ART Users: 38.7%) and diabetes (HIV-negative: 
12.0%, HIV+/No ART: 6.3%, HIV+/ART users: 7.8%) when compared to the HIV-negative 
population though the prevalence of these conditions remains high across all three groups.
Table 1 also describes self-reported utilization of care for hypertension and diabetes in ART 
users compared to non-ART users in the HAALSI cohort. The percentage of participants 
who received a blood pressure or blood sugar measurement or counseling from a healthcare 
provider regarding exercise was greater among ART-users as compared to non-ART users 
(HIV-negative: 70.0%, 48.7% and 5.5%, HIV+/No ART: 69.2%, 42.1% and 1.3%, HIV
+/ART Users: 71.5%, 49.0% and 7.8%), as was awareness of diagnosis and treatment for 
hypertension (HIV-negative: 65.2% and 56.5%, HIV+/No ART: 59.6% and 49.1%, HIV
+/ART Users: 67.6% and 57.8%) and diabetes (HIV-negative: 55.9% and 53.9%, HIV+/No 
ART: 47.8% and 43.5%, HIV+/ART Users: 56.9% and 54.9%). These differences were only 
statistically significant for blood sugar measurement and counseling to exercise.
ART and utilization of healthcare services for diabetes and hypertension
Multivariable logistic regression models of diagnosis and preventive counseling for diabetes 
and hypertension (Table 2) showed greater odds of ever receiving a blood pressure 
measurement (adjusted odds ratio [aOR] 1.27 95% CI 1.04–1.55), blood sugar measurement 
(aOR 1.26, 95% CI 1.05–1.51) or counseling regarding exercise (aOR 1.57, 95% CI 1.11–
2.22) among HIV+/ART users as compared to those who were HIV-negative, after adjusting 
for age, sex, BMI, education and household wealth quintile. However, the odds of receiving 
preventive counseling from a healthcare provider regarding diet (aOR: 1.24, 95% CI: 0.92 – 
1.67) among the HIV+/ART users was not statistically significant.
Regression analyses (Table 3) also demonstrated greater odds of being aware of a diagnosis 
of hypertension among those hypertensive participants who were HIV+/ART users (aOR 
1.52, 95% CI 1.12–2.05) as compared to those who were HIV-negative. The HIV+/ART 
group also had greater odds of receiving treatment for their hypertension and treatment (aOR 
1.63, 95% CI 1.21–2.19), again compared to those who were HIV-negative. Relationships of 
similar magnitude were seen between ART use and awareness of diabetes diagnosis or 
treatment of diabetes, but these were not statistically significant due to lower prevalence of 
diabetes diagnosis and treatment. Though not shown in Tables 2 and 3, all of these 
relationships were equally strong and significant among the sub-group of self-reported ART 
users and among those who were ART users and virally suppressed (see Supplementary 
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Appendix). There was no qualitative difference in the results at alternative thresholds of viral 
suppression.
DISCUSSION
This study offers several key findings regarding the relationship between HIV infection, 
ART use and utilization of health services for hypertension and diabetes, two major non-
communicable diseases of increasing importance in this region. First, in a community with 
very high HIV, hypertension and diabetes prevalence, ART utilization is associated with 
utilization of needed hypertension and diabetes care, including greater diagnostic testing and 
preventive counseling regarding lifestyle modification for diabetes and hypertension as well 
as treatment among those affected by these comorbid chronic diseases. This rural South 
African cohort was well-suited to examining these relationships given the high prevalence of 
HIV and the similarly high rates of both hypertension and diabetes in this group of older 
adults.
However, due to the cross-sectional nature of this study, it is unknown whether ART use 
actually precedes the diagnosis and treatment of NCDs or vice versa. The mechanism for the 
association between these services is unclear but may include better access to or utilization 
of healthcare services generally, increased exposure to health information resulting in better 
health literacy and more accurate self-reporting of service utilization, more assertive health-
seeking behavior or some combination of these factors. One important factor underlying this 
finding may be that those on ART are required to present to a clinic each month to obtain 
medications and thus likely come into contact with the health system much more frequently 
than HIV-negative or HIV-positive people who are not receiving ART. The frequency of this 
contact may offer more opportunities to be diagnosed, educated or referred to chronic 
disease clinical staff for care of other health conditions. The data presented here suggest a 
potential positive spillover effect from ART utilization to care for other chronic conditions. 
If true, this may suggest a more central role for ART programs in the delivery of care for 
NCDs among HIV-positive populations, in particular screening, diagnosis and preventive 
care for the increasingly large population initiating ART in this context.
Our results found that awareness of a hypertension diagnosis is also greater among those 
hypertensive participants in the HIV+/ART group. ART users who were also hypertensive 
were also more likely to self-report receiving treatment for their hypertension. However, 
similar relationships did not exist for awareness of a diabetes diagnosis or treatment of 
diabetes, though the small number of people with diabetes in the sample may limit the power 
to draw definitive conclusions regarding this relationship.
In addition, we found a high prevalence of both diabetes and hypertension in this rural South 
African community specifically among the population over age 40. Though these conditions 
have not received nearly the same level of attention as HIV, several recent studies in similar 
settings in Southern Africa have shown comparable prevalence estimates for both diabetes 
and hypertension in aging African adults.5–7 This lends further evidence that the burden of 
these two cardiovascular risk factors is very important in middle-income countries and that 
failing to address these chronic diseases could have detrimental effects on the population-
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level gains in life expectancy and quality of life that have been achieved through ART roll-
out.2,29 However, we also show that HIV-positive participants in this rural South African 
cohort (HIV+/No ART and HIV+/ART) have a lower prevalence of diabetes and 
hypertension as compared to the HIV-negative population. The lower prevalence of these 
conditions is likely multifactorial as PLWHIV are on average younger and have a lower BMI 
than the HIV-negative participants. In particular, their lower BMI may be in part caused by 
their HIV disease and would be expected to reduce their risk of diabetes and hypertension, 
though they remain at heightened risk of other opportunistic infections.4,30
However, the fact that the prevalence of diabetes and hypertension remains high in the 
setting of relatively younger age and lower BMI among PLWHIV may also indicate the 
potential for an increasing burden of these conditions in the future with the shift toward early 
ART initiation in HIV disease.31 In particular, early ART initiation may be expected to 
promote body weight preservation by averting HIV-associated wasting among infected 
populations, in contrast to older guidelines that recommended ART initiation at a later stage 
of immunosuppression. Perhaps paradoxically, this could result in even greater rates of 
hypertension, diabetes and other non-communicable diseases among the HIV-positive 
population in the future. As shown in this study, greater counseling on healthy lifestyle 
habits for HIV-positive people on ART may lead to improvements in diet and increased 
physical activity, thereby mitigating the effects of earlier ART initiation on NCDs.
While these findings provide important insight regarding the design and delivery of care for 
diabetes and hypertension among PLWHIV, they may also provide lessons that are relevant 
to care delivery for these conditions in the HIV negative population. When considering 
possible overlap between the health systems infrastructure underlying HIV care programs 
and the health systems structures needed to support growing epidemics of diabetes and 
hypertension,32,33 these findings suggest that ART programs may serve as a powerful 
platform for broader population health improvements via increased programmatic 
integration.34 One excellent example of the potential for this integration has been the 
Academic Model Providing Access to Healthcare (AMPATH) program which provides care 
to >150,000 adults and children living with HIV/AIDS throughout Western Kenya.35 This 
collaboration has been able to provide important insights about cardiometabolic diseases in 
PLWHIV, including high rates of cardiovascular risk, low levels of knowledge and perceived 
risk of cardiovascular disease in this population.35 Another example of this may be the Ideal 
Clinics Initiative in South Africa, a reform effort which in part involves integrating some 
aspects of care for HIV with care for common chronic conditions such as diabetes and 
hypertension.36 Finally, the expansion of universal health coverage will potentially be 
advanced by the integration of services for common, key conditions such as HIV, diabetes 
and hypertension.
This study has several limitations. First, data on utilization of health services for NCDs were 
self-reported, including the diagnosis and care received for both diabetes and hypertension. 
Despite this limitation, in the case of diagnosis and preventive counseling for these NCDs, 
the use of self-reported data can be illuminating because it not only reflects the health 
services participants have received but also their understanding of both those diagnostic tests 
and advice. In the case of counseling on lifestyle modification, this is particularly relevant 
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given that this type of advice can seemingly only be used in a meaningful way if the 
recipient understands and retains the information provided. However, the limitation of self-
reported data includes misreporting and the direction of any resulting bias is difficult to 
predict. A second limitation of this study is the lack of temporal data regarding the date and 
duration of HIV infection, the time when ART was initiated and the timing during which 
services were received for diabetes and hypertension. Without this information, it is difficult 
to assess the directionality of the relationship between ART program participation and 
receipt of care for NCDs. Finally, there are various definitions of viral suppression that could 
be acceptable in the South African context; however, the supplementary analyses for this 
population showed a preserved association between virally suppressed ART users and the 
outcomes of interest across four commonly used thresholds.
In summary, this analysis supports the findings that the burden of non-communicable 
diseases is substantial among the HIV-positive population in Agincourt. The HIV-positive 
population that was receiving ART also reported greater access to diagnosis and preventive 
counseling for diabetes and hypertension, two major non-communicable diseases in South 
Africa, as well as awareness of diagnosis and treatment of hypertension. This relationship 
was not preserved for the awareness of diabetes diagnosis and treatment of diabetes, but 
small sample sizes may limit the power to show this relationship. The positive spillover 
effects from ART utilization to preventive care for other chronic conditions could provide a 
powerful vehicle for broader population health improvements via increased programmatic 
integration.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We would like to thank Shahira Ahmed, ScD for her support in the preparation of this manuscript.
Funding Statement
This work was supported by the National Institute of Aging at the National Institutes of Health (grant numbers 
1P01AG041710-01A1, HAALSI –Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community 
in South Africa and P30AG024409, for the Program on the Global Demography of Aging at Harvard University). 
The content is solely the responsibility of the authors and does not necessarily represent the official views of the 
National Institutes of Health. The HAALSI study is nested within the Agincourt Health and socio-Demographic 
Surveillance System site, funded by the University of the Witwatersrand and Medical Research Council, South 
Africa, and the Wellcome Trust, UK (058893/Z/99/A; 069683/Z/02/Z; 085477/Z/08/Z; 085477/B/08/Z).
References
1. World Health Organization. Global update on HIV treatment. Geneva: World Health Organization; 
2013. 2013. 
2. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South 
Africa: valuing the scale-up of HIV treatment. Science. 2013; 339(6122):961–5. [PubMed: 
23430655] 
3. Hontelez JA, de Vlas SJ, Baltussen R, et al. The impact of antiretroviral treatment on the age 
composition of the HIV epidemic in sub-Saharan Africa. AIDS. 2012; 26(Suppl 1):S19–30. 
[PubMed: 22781175] 
Manne-Goehler et al. Page 9
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Feigl AB, Bloom DE, Danaei G, et al. The Effect of HIV and the Modifying Effect of Anti-
Retroviral Therapy (ART) on Body Mass Index (BMI) and Blood Pressure Levels in Rural South 
Africa. PLoS One. 2016; 11(8):e0158264. [PubMed: 27552195] 
5. Werfalli M, Engel ME, Musekiwa A, Kengne AP, Levitt NS. The prevalence of type 2 diabetes 
among older people in Africa: a systematic review. Lancet Diabetes Endocrinol. 2015
6. Lloyd-Sherlock P, Beard J, Minicuci N, Ebrahim S, Chatterji S. Hypertension among older adults in 
low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol. 2014; 43(1):
116–28. [PubMed: 24505082] 
7. Kaze AD, Schutte AE, Erqou S, Kengne AP, Echouffo-Tcheugui JB. Prevalence of hypertension in 
older people in Africa: a systematic review and meta-analysis. J Hypertens. 2017
8. Bloomfield GS, Khazanie P, Morris A, et al. HIV and noncommunicable cardiovascular and 
pulmonary diseases in low- and middle-income countries in the ART era: what we know and best 
directions for future research. J Acquir Immune Defic Syndr. 2014; 67(Suppl 1):S40–53. [PubMed: 
25117960] 
9. Barnighausen T, Welz T, Hosegood V, et al. Hiding in the shadows of the HIV epidemic: obesity and 
hypertension in a rural population with very high HIV prevalence in South Africa. J Hum 
Hypertens. 2008; 22(3):236–9. [PubMed: 18046436] 
10. Ameh S, Gomez-Olive FX, Kahn K, Tollman SM, Klipstein-Grobusch K. Predictors of health care 
use by adults 50 years and over in a rural South African setting. Glob Health Action. 2014; 
7:24771.
11. Clark SJ, Gomez-Olive FX, Houle B, et al. Cardiometabolic disease risk and HIV status in rural 
South Africa: establishing a baseline. BMC Public Health. 2015; 15:135. [PubMed: 25885455] 
12. Gomez-Olive FX, Thorogood M, Clark B, Kahn K, Tollman S. Self-reported health and health care 
use in an ageing population in the Agincourt sub-district of rural South Africa. Glob Health 
Action. 2013; 6:19305.
13. The Lancet Diabetes E. HIV and NCDs: the need to build stronger health systems. Lancet Diabetes 
Endocrinol. 2016; 4(7):549–50. [PubMed: 27290621] 
14. Yu D, Souteyrand Y, Banda MA, Kaufman J, Perriens JH. Investment in HIV/AIDS programs: does 
it help strengthen health systems in developing countries? Global Health. 2008; 4:8. [PubMed: 
18796148] 
15. England R. The dangers of disease specific programmes for developing countries. BMJ. 2007; 
335(565)
16. Shiffman J. Has donor prioritization of HIV/AIDS displaced aid for other health issues? Health 
Policy Plan. 2008; 23(2):95–100. [PubMed: 18156161] 
17. McCoy D, Chopra M, Loewenson R, et al. Expanding access to antiretroviral therapy in sub-
saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities. Am J Public 
Health. 2005; 95(1):18–22. [PubMed: 15623853] 
18. Atun R, Gale EA. The challenge of diabetes in sub-Saharan Africa. Lancet Diabetes Endocrinol. 
2015; 3(9):675–7. [PubMed: 26201978] 
19. Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. Heart. 2008; 
94(11):1376–82. [PubMed: 18519551] 
20. Joint United Nations Programme on HIV/AIDS (UNAIDS) Chronic care of HIV and 
noncommunicable diseases: Joint United Nations Programme on HIV/AIDS (UNAIDS) 2011
21. Kahn K, Collinson MA, Gomez-Olive FX, et al. Profile: Agincourt health and socio-demographic 
surveillance system. Int J Epidemiol. 2012; 41(4):988–1001. [PubMed: 22933647] 
22. Rosenberg MS, Gomez-Olive FX, Rohr JK, et al. Sexual Behaviors and HIV Status: A Population-
Based Study Among Older Adults in Rural South Africa. J Acquir Immune Defic Syndr. 2017; 
74(1):e9–e17. [PubMed: 27926667] 
23. Gaziano TA, Abrahams-Gessel S, Gomez-Olive FX, et al. Cardiometabolic risk in a population of 
older adults with multiple co-morbidities in rural south africa: the HAALSI (Health and Aging in 
Africa: longitudinal studies of INDEPTH communities) study. BMC Public Health. 2017; 17(1):
206. [PubMed: 28212629] 
Manne-Goehler et al. Page 10
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
24. Kim AA, Mukui I, Young PW, et al. Undisclosed HIV infection and antiretroviral therapy use in 
the Kenya AIDS indicator survey 2012: relevance to national targets for HIV diagnosis and 
treatment. AIDS. 2016; 30(17):2685–95. [PubMed: 27782965] 
25. Koal T, Burhenne H, Romling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral 
drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. 
Rapid Commun Mass Spectrom. 2005; 19(21):2995–3001. [PubMed: 16193530] 
26. United States Centers for Disease Control and Prevention. National Health and Nutrition 
Examination Survey: 1999–2000 Data Documentation, Codebook, and Frequencies. Washington, 
D.C.: 2015. 
27. Society for Endocrinology Metabolism and Diabetes of South Africa. The 2012 SEMDSA 
Guideline for the Management of Type 2 Diabetes Mellitus: Summary. South Africa: Society of 
Endocrinology, Metabolism and Diabetes in South Africa; 2012. 
28. World Health Organization. Definition and Diagnosis of Diabetes and Intermediate 
Hyperglycemia. Geneva: 2006. 
29. Bor J, Tanser F, Newell ML, Barnighausen T. In a study of a population cohort in South Africa, 
HIV patients on antiretrovirals had nearly full recovery of employment. Health Aff (Millwood). 
2012; 31(7):1459–69. [PubMed: 22778335] 
30. Geldsetzer P, Feigl AB, Tanser F, Gareta D, Pillay D, Barnighausen T. Population-level decline in 
BMI and systolic blood pressure following mass HIV treatment: Evidence from rural KwaZulu-
Natal. Obesity (Silver Spring). 2016
31. Insight Start Study Group. Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in 
Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795–807. [PubMed: 26192873] 
32. World Health Organization. Universal Health Coverage: Questions and Answers. 2015. http://
www.who.int/healthsystems/topics/financing/uhc_qa/en/ (accessed December 11 2015)
33. Reich MR, Harris J, Ikegami N, Maeda A, Takemi K, Evans TG. Moving towards universal health 
coverage: lessons from 11 country studies. Lancet. 2015
34. Tollman SM, Kahn K, Sartorius B, Collinson MA, Clark SJ, Garenne ML. Implications of 
mortality transition for primary health care in rural South Africa: a population-based surveillance 
study. Lancet. 2008; 372(9642):893–901. [PubMed: 18790312] 
35. Temu TM, Kirui N, Wanjalla C, et al. Cardiovascular health knowledge and preventive practices in 
people living with HIV in Kenya. BMC Infect Dis. 2015; 15:421. [PubMed: 26466584] 
36. Mahomed OH, Asmall S, Freeman M. An integrated chronic disease management model: a 
diagonal approach to health system strengthening in South Africa. J Health Care Poor 
Underserved. 2014; 25(4):1723–9. [PubMed: 25418238] 
Manne-Goehler et al. Page 11
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
HIV Infection, ART Use and Viral Suppression in the HAALSI Cohort, Agincourt sub-
district, South Africa 2015
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Table 1
Demographic characteristics, cardiometabolic risk factors and healthcare utilization by HIV and ART status in 
the HAALSI Cohort
Indicator HIV-negative HIV+/No ART HIV+/ART p
Total 3512 373 662 –
Age – Mean 63.6 54.5 55.9 <0.001
Female (%) 54.0 57.3 52.3 0.286
BMI – Mean 27.7 26.8 25.3 <0.001
Diabetic (%) 12.0 6.3 7.8 <0.001
SBP – Mean 140 132 129 <0.001
Hypertensive (%) 63.7 43.5 38.7 <0.001
Ever Blood Pressure 70.0 69.2 71.5 0.692
Ever Blood Sugar 48.7 42.1 49.0 0.049
Told to Change Diet 11.3 6.4 9.7 0.011
Told to Exercise 5.5 1.3 7.8 <0.001
Told Hypertension 65.2 59.6 67.6 0.245
Told Diabetes 55.9 47.8 56.9 0.737
Treated Hypertension 56.5 49.1 57.8 0.159
Treated Diabetes 53.9 43.5 54.9 0.609
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Table 2
Multivariate logistic regression results: ART and diabetes and hypertension diagnosis and preventive 
counseling in Agincourt, South Africa
Covariates
Ever Blood Pressure
aOR + 95% CI
Ever Sugar
aOR + 95% CI
Advised Change Diet
aOR + 95% CI
Told to Exercise
aOR + 95% CI
Age 1.02***
(1.01 – 1.02)
1.02***
(1.01 – 1.02)
1.02***
(1.01 – 1.03)
1.00
(0.99 – 1.02)
Female 1.44***
(1.25 – 1.67)
1.18**
(1.04 – 1.35)
1.38***
(1.10 – 1.72)
0.94
(0.71 – 1.26)
Overweight 0.87*
(0.74 – 1.03)
1.35***
(1.155 – 1.571)
1.18
(0.90 – 1.54)
1.20
(0.84 – 1.71)
Obese 1.03
(0.86 – 1.23) 1.49
***
(1.26 – 1.75)
1.81***
(1.39 – 2.35)
1.79***
(1.26 – 2.53)
Education 1–7 1.08
(0.91 – 1.27) 1.25
***
(1.07 – 1.45)
1.39***
(1.09 – 1.77)
2.23***
(1.56 – 3.18)
Education 8–11 1.13
(0.88 – 1.45) 1.46
***
(1.16 – 1.84)
0.88
(0.58 – 1.34) 2.90
***
(1.82 – 4.63)
Education 12+ 0.75**
(0.59 – 0.96)
1.25*
(0.99 – 1.58)
0.95
(0.64 – 1.43) 1.95
**
(1.17 – 3.27)
Wealth Quintile 2 1.05
(0.85 – 1.30)
1.05
(0.86 – 1.28)
0.79
(0.56 – 1.13)
0.92
(0.54 – 1.56)
Wealth Quintile 3 1.26**
(1.02 – 1.57)
1.16
(0.95 – 1.42)
0.93
(0.66 – 1.31)
1.21
(0.739 – 1.99)
Wealth Quintile 4 1.20
(0.96 – 1.49) 1.38
***
(1.12 – 1.69)
1.11
(0.79 – 1.55)
1.39
(0.86 – 2.27)
Wealth Quintile 5 1.47***
(1.17 – 1.85)
1.53***
(1.24 – 1.89)
1.51**
(1.08 – 2.10)
1.62**
(1.00 – 2.61)
HIV+/No ART 1.11
(0.86 – 1.42)
0.94
(0.74 – 1.18)
0.71
(0.45 – 1.12) 0.26
***
(0.10 – 0.63)
HIV+/ART 1.27**
(1.04 – 1.55)
1.26**
(1.05 – 1.51)
1.24
(0.92 – 1.67) 1.57
**
(1.11 – 2.22)
Constant 0.61**
(0.39 – 0.97)
0.19***
(0.13 – 0.29)
0.02***
(0.01 – 0.03)
0.02***
(0.01 – 0.05)
Observations 4,134 4,134 4,134 4,132
95% CI in parentheses
***p<0.01,
**p<0.05,
*p<0.1
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Table 3
Multivariate logistic regression results: ART and diabetes and hypertension awareness and care in Agincourt, 
South Africa
Covariates
Told Hypertension
aOR + 95% CI
Told Diabetes
aOR + 95% CI
Treated Hypertension
aOR + 95% CI
Treated Diabetes
aOR + 95% CI
Age 1.03***
(1.02 – 1.04)
1.01
(0.99 – 1.03) 1.04
***
(1.030 – 1.05)
1.01
(0.99 – 1.03)
Female 1.69***
(1.41 – 2.03)
0.99
(0.65 – 1.53) 1.77
***
(1.48 – 2.12)
0.98
(0.64 – 1.50)
Overweight 1.58***
(1.27 – 1.97)
1.06
(0.61 – 1.82) 1.63
***
(1.32 – 2.03)
1.09
(0.63 – 1.87)
Obese 2.22***
(1.77 – 2.79)
1.04
(0.61 – 1.77) 2.28
***
(1.83 – 2.84)
1.13
(0.67 – 1.92)
Education 1–7 1.22*
(0.97 – 1.52)
1.11
(0.70 – 1.75)
1.11
(0.90 – 1.36)
1.08
(0.69 – 1.71)
Education 8–11 0.81
(0.59 – 1.13)
0.96
(0.44 – 2.09)
0.80
(0.58 – 1.09)
0.95
(0.44 – 2.06)
Education 12+ 0.95
(0.67 – 1.33)
1.67
(0.75 – 3.75)
0.82
(0.58 – 1.14)
1.66
(0.74 – 3.69)
Wealth Quintile 2 0.97
(0.74 – 1.29)
0.89
(0.42 – 1.89)
0.99
(0.75 – 1.31)
0.915
(0.43 – 1.94)
Wealth Quintile 3 1.38**
(1.04 – 1.84)
1.13
(0.54 – 2.37) 1.27
*
(0.96 – 1.69)
1.11
(0.53 – 2.33)
Wealth Quintile 4 1.48***
(1.11 – 1.96)
1.15
(0.56 – 2.37) 1.47
***
(1.11 – 1.94)
1.11
(0.54 – 2.29)
Wealth Quintile 5 1.80***
(1.34 – 2.42)
1.54
(0.73 – 3.23) 1.79
***
(1.34 – 2.39)
1.52
(0.72 – 3.19)
HIV+/No ART 1.16
(0.80 – 1.66)
0.98
(0.39 – 2.51)
1.09
(0.76 – 1.55)
0.89
(0.35 – 2.28)
HIV+/ART 1.52***
(1.12 – 2.05)
1.33
(0.69 – 2.56) 1.63
***
(1.21 – 2.19)
1.35
(0.71 – 2.60)
Constant 0.09***
(0.05 – 0.19)
0.38
(0.09 – 1.66) 0.04
***
(0.02 – 0.08)
0.33
(0.08 – 1.44)
Observations 2,387 428 2,388 427
95% CI in parentheses
***p<0.01,
**p<0.05,
*p<0.1
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